Fifty 410
Fifty 410 offers provider-reviewed compounded GLP-1 programs without a required subscription. Its current disclosures and earlier FDA advertising warning both matter.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The pay-after-prescribing process and clear program totals are useful. Confirm the actual clinician, pharmacy and administration details, and consider the FDA record alongside the current revised disclosures.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
FDA warning letter on record: Letter 721481 · February 2026
Fifty 410 is a telehealth platform offering compounded semaglutide and tirzepatide programs. It says it does not manufacture, compound or distribute the medication. An independent provider decides whether to prescribe, and an independent pharmacy prepares an approved order. The current catalog also lists NAD+, sermorelin and other additions as coming soon. Those are not established active treatment choices merely because they have product pages. A patient should distinguish the currently available GLP-1 programs from the waitlist options when deciding whether the service fits a particular goal.
What Fifty 410 prescribes, by goal
Weight
- SemaglutideFDA-approved
- Injection (compounded)Price not published
- TirzepatideFDA-approved
- Injection (compounded)Price not published
Compounded semaglutide and tirzepatide are the active named programs. Their current pages emphasize independent prescribing and do not promise a particular amount of weight loss. The expanded program FAQ explicitly identifies both medicines as subcutaneous injections. The concentration and schedule still need to come from the prescription and pharmacy instructions. A general calculator or illustrative product photograph should not replace that individual guidance.
Who prescribes
A licensed clinician
The clinical network is described through independent licensed providers and a practice identified in the HIPAA notice as Aspen Aesthetics PLLC doing business as Fifty 410. The platform terms instead use Aspen Aesthetics LLC. That distinction needs clarification rather than treating the company name as an assigned clinician. The patient-rights page says the treating provider’s identity, professional entity and licensure should be available before care. Obtain those details for the actual appointment. The public material does not establish a named individual clinician for every applicant or a fixed dispensing pharmacy for every prescription.
An applicant submits medical information without a credit card, then completes a provider appointment through the secure portal. Only after a prescription is issued does the patient review the program and receive a payment link. Ongoing follow-up through the portal is included in the program description. The consent allows telephone, video or messaging according to the service and professional judgment; it does not promise an identical live encounter for everyone. Ask how the appointment works and how the clinician handles symptoms that need further testing or an in-person examination. Payment after review is useful, but it does not make a prescription automatic.
Are labs required?
Not mentioned
The public GLP-1 program summaries do not establish a standard included laboratory package or universal testing schedule. The refund terms separately mention laboratory services once performed, which does not show that every applicant is required to buy them. Ask what recent results are needed, whether outside testing can be accepted and what additional charges may apply. The clinician should explain how abnormal findings are followed up. A review that occurs before payment is not evidence that bloodwork or further examination can never be necessary.
Ready to start with Fifty 410?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
FDA sent Aspen Aesthetics doing business as Fifty 410 warning letter 721481 in February 2026. It concerned earlier website representations, including labels suggesting the platform compounded medicines and claims about clinically proven ingredients. That is an advertising and misbranding record, not a finding that a particular patient’s vial failed sterility testing. The current website clearly states that the platform does not compound medication and that compounded products are not FDA-approved. Those changes are relevant, but they are not proof that FDA has verified compliance. The queried warning-letter index does not link a closeout for that letter. Keep the historical concern and the current observable wording separate.
How it bills
The current price page offers semaglutide for $199 over four weeks and tirzepatide for $199 over four weeks or $299 over eight weeks. The lower tirzepatide equivalent belongs to the longer program, not a separate calendar-month purchase. No subscription or membership is required, and the program includes consultation and refrigerated delivery. Once an approved order is paid, the refund policy permits cancellation only if confirmed before compounding begins. It preserves remedies for verified errors, loss, compromised shipments or inability to fulfill. Ask the pharmacy to clarify the preparation and instructions before paying for the full supplied period.
For and against
- For: Payment follows the provider’s prescribing decision
- For: Independent four-week program totals are displayed
- For: Portal follow-up and refrigerated shipping are included
- For: Current pages clearly distinguish the platform from the compounder
- Against: Earlier FDA advertising warning deserves consideration
- Against: Platform and practice legal suffixes differ
- Against: Assigned clinician, pharmacy and preparation details need confirmation
- Against: Routine cancellation ends when compounding begins
The evidence behind what it sells
Right for
Someone comfortable with provider-reviewed compounded GLP-1 care who wants to buy programs as needed and will verify the actual treatment details first.
Look elsewhere if
A patient expecting active access to the coming-soon longevity catalog, a guaranteed prescription or a refund after ordinary compounding has started.
Other sellers for weight
Fresh Day Meds
Also prescribes Semaglutide, Tirzepatide.
Genesis Health
Also prescribes Semaglutide, Tirzepatide.
Royal Medical Center
Also prescribes Semaglutide, Tirzepatide.
Fifty 410
Frequently asked questions
- Are NAD+ and sermorelin currently available?
- Their current pages say coming soon and offer a waitlist. They should not be treated as active prescriptions or priced programs.
- Does the FDA letter establish a sterility problem in every prescription?
- No. The letter concerns website claims and manufacturer representations. It does not establish that a particular supplied vial was affected.
- When does routine cancellation become restricted?
- The refund policy makes the start of compounding the key cutoff. Cancellation must be received and confirmed before that point.
Sources
- Care and treatment: Current GLP-1 offer
- Care and treatment: Independent program totals
- Care and treatment: Semaglutide purchase period
- Care and treatment: Tirzepatide purchase choices
- Care and treatment: Independent providers and service terms
- Care and treatment: Practice identity and patient rights
- Care and treatment: Refund and compromised-delivery policy
- Care and treatment: Earlier advertising warning
See what Fifty 410 prescribes today
Fifty 410 sets its own prices, plans and the states it serves. Check them before you start.